Ernexa Therapeutics Inc. · NASDAQ:ERNA

Ernexa Therapeutics — Brooklyn ImmunoTherapeutics — Investor Presentation (November 2021)

30 slides from Ernexa Therapeutics's investor presentation, Nov 12, 2021

1. Slide 1: mRNA Engineered Cell & Genetic Medicines

   mRNA Engineered Cell & Genetic Medicines November 2021 A platform company in cell, ​gene-editing & cytokine therapies

2. Slide 2: Disclaimer

   Disclaimer This presentation is intended to provide summary information about the business of Brooklyn ImmunoTherapeutics, Inc. (“BTX”). The information in this presentation is in no respects complete, comprehensive or exhaustive, and it should be read in conjunction with BTX’s public filings with t

3. Slide 3: BTX is Led by a Strong, Experienced Management Team

   Howard FederoffMD, PhDChief Executive Officer and President Kevin D’AmourPhDChief Scientific Officer Ron Guido, MS Pharm. Med.Chief Development Officer Roger SidhuMDChief Medical Officer Jay SialMBAChief Administrative Officer Sandra GurrolaVP of Finance BTX is Led by a Strong, Experienced Managemen

4. Slide 4: BTX Transforms into Regenerative Medicine Company with Platform Technology

   BTX Transforms into Regenerative Medicine Company with Platform Technology Reverse merger Exclusive license to mRNA and LNP patents Secured $55M in Capital* Acquired Novellus Therapeutics Recruited new Exec team Nasdaq listing(from NYSE American) 2021 * Runway into 2023 4

5. Slide 5: Leveraging In-licensed Patent Portfolio to Advance Medicine

   Leveraging In-licensed Patent Portfolio to Advance Medicine BTX has an exclusive license from Factor Bioscience to a portfolio of granted patents around mRNA-based cell engineering that will provide a competitive advantageMajor platform components: mRNA Cell Reprogramming (25 patents, extensive cell

6. Slide 6: BTX has a Broad Technology Landscape

   mRNA therapeutics Non-viralgenetic medicines Footnote: doesn’t represent ex vivo gene editing space In Vivo gene editing iPSC-derivedtherapies BTX has a Broad Technology Landscape 6

7. Slide 7: Brooklyn's Licensed mRNA-Based and LNP Technologies

   Brooklyn’s Licensed mRNA-Based and LNP Technologies Cell reprogramming Gene editing mRNA and LNP are toolsto make engineered cell medicine Nucleic acid delivery mRNA and LNP are the drugas in vivo gene-editing medicine 7

8. Slide 8: The Foundational mRNA Cell Reprogramming Platform

   The Foundational mRNA Cell Reprogramming Platform Typical Results Highest efficiency generation of iPSC: 5 factors, rapid protein expressionLow toxicity, high percentage transfectedCustom reprogramming mediaSafe: no chance of genome integrationCan combine reprogramming with gene editing to streamlin

9. Slide 9: Unique mRNA-Based Delivery of a Novel Gene Editing Platform

   Unique mRNA-Based Delivery of a Novel Gene Editing Platform Gene Knockout Gene Repair Safe-harbor Insertion Use of mRNA for Delivering Gene-Editing ProteinsRapid, high expression (efficiency)Transient expression (specificity)Amenable to non-viral deliveryNo risk of vector insertionMultiple in-licens

10. Slide 10: Novel Lipid with Effective mRNA Delivery In Vitro and In Vivo

    Novel Lipid with Effective mRNA Delivery In Vitro and In Vivo U.S. Pat. No. 10,501,404 A compound of Formula (I) Wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, or 15. Novel, single lipid component LNPNovel lipid, composition of matter IPLow toxicity enables repeated transfectionEfficient

11. Slide 11: Platform Technology Deployed in Four Regenerative Medicine Pillars

    Platform Technology Deployed in Four Regenerative Medicine Pillars Allogenic Stem CellPlatform (iMSC)ARDS​Bone marrow transplant failure/poor functionSolid tumors​ Autologous, Gene Edited PlatformHemoglobinopathiesOpportunities in many genetic diseases Autologous iPSCPlatformParoxysmal nocturnal hem

12. Slide 12: Allogeneic iMSC Therapies

    Fil Brooklyn Allogeneic iMSC Therapies

13. Slide 13: Allogeneic iMSC Product Platform

    Allogeneic iMSC Product Platform iPSC-derived Mesenchymal Stem Cells (iMSC)Low risk of toxicity, proven across many clinical studiesLow immunogenicity, no need for immunosuppressive drugsLeveraging decades of work with MSC process development and manufacturingA single Drug Product can be used across

14. Slide 14: Brooklyn's iMSC Address Issues with Tissue-derived MSC

    Brooklyn’s iMSC Address Issues with Tissue-derived MSC Historical Issues with MSC field Tissue-derived MSC Brooklyn’s iMSC Donor to donor variability Tissue source variability Manufacturing variability Limited or inconsistent characterization Poor mechanistic understanding Capacity to precisely gene

15. Slide 15: Extensive Characterization of iMSC to Ensure Consistency

    Extensive Characterization of iMSC to Ensure Consistency Characterization to include:Stability of phenotypes with progressive passagesChanging responses to hypoxia and other stimuli Single cell RNA-seq Mass Cytometry Secretome Kehl et. A. (2019) Hutton et. A. (2021) Liu et. A. (2019) 15

16. Slide 16: iMSC Application in Graft Failure/Poor Graft Function

    MSCs modulate immunological responses, support hematopoiesis, and repair bone marrow stromaClinical applications in hematopoietic stem cell transplant (HSCT)Treating engraftment failure or poor graft function​Promoting HSC engraftment​Working with world class KOLs in HSCT to focus on best clinical p

17. Slide 17: Developing a Family of Gene-edited iMSC Products for Solid Tumors

    Gene-editing iPSC and thorough characterization; followed by differentiation to iMSC​Multiple engineered iMSC products to deliver agents locally and avoid systemic toxicities​IL-7 & IL-15 drive expansion and engraftment​Combination with CAR-T and checkpoint inhibitors​ Developing a Family of Gene-ed

18. Slide 18: Autologous Cell Therapies

    Fis Brooklyn Oia ImmunoTherapeutic: Autologous Cell Therapies

19. Slide 19: Autologous Cell Therapy, Efficient mRNA Gene Editing

    Autologous Cell Therapy, Efficient mRNA Gene Editing Autologous HSC-based gene therapy for many addressable indicationsHemoglobinopathies Primary immunodeficienciesCongenital cytopeniasLeverages 30 years of clinical experience and isolation techniques for CD34+ HSC; robust engraftment and safetymRNA

20. Slide 20: Autologous iPSC Therapies

    Fil Brooklyn Autologous iPSC Therapies

21. Slide 21: Autologous iPSC Cell Therapy Platform

    Autologous iPSC Cell Therapy Platform Licensed technology is the safest, most efficient, and fastest method for iPSC derivation Safe: Non-integrating method using synthetic mRNA to produce reprogramming factorsEfficient: Uses LNP for repeated in vitro delivery with low toxicityEfficient: Can combine

22. Slide 22: Autologous HSC from iPSC

    Autologous HSC from iPSC Autologous iPSC / Gene-modified autologous iPSC for: Genetic disease (e.g. hemoglobinopathies)Paroxysmal nocturnal hemoglobinuria (PIG1A)Infectious disease 22

23. Slide 23: In Vivo Gene Editing Therapies

    In Vivo Gene Editing Therapies

24. Slide 24: Second Pillar is a Genetic Medicine Product Platform

    Second Pillar is a Genetic Medicine Product Platform Proprietary lipid nanoparticle for nucleic acid deliveryNovel lipid with composition of matter IPProperties can be tuned to target different cell types and tissuesCan deliver RNA or DNA; facilitates gene correction approachesDelivery of mRNA encod

25. Slide 25: Developing In Vivo Gene-editing Products Addressing Rare Disease Indications

    Developing In Vivo Gene-editing Products Addressing Rare Disease Indications (Orphan Designation) Direct gene editing in the liver, brain or eye for monogenic disordersAbility to knock-out or correct the target geneInitial gene target is knock-out of TTR for Familial Transthyretin Amyloidosis (ATTR)

26. Slide 26: Amyloidosis Caused by Transthyretin (ATTR)

    Amyloidosis Caused by Transthyretin (ATTR) Caused by misfolded transthyretin (TTR), aggregating into toxic oligomeric forms​​Death 5-15 years after onset of symptoms is typical​Non-Familial (200,000-500,000 worldwide)​Owing to tissue deposition of normal TTR amyloid​Common clinical feature is periph

27. Slide 27: Clinical Features of Familial ATTR

    Three sites of TTR synthesis, determine distinct clinical phenotypes​Liver: cardiomyopathy, peripheral neuropathy​Choroid plexus: LeptomeningealNeuroretina: Ocular toxicity​​ Current treatments address only liverFull phenotypic recovery requires both hepatic and CNS/choroid plexus intervention​Brook

28. Slide 28: BTX In Vivo Editing Addresses all ATTR Manifestations

    ​ Polyneuropathy​ ​Cardiomyopathy​ ​Ocular depositions​ Leptomeningeal depositions​ ​Subtype​ Observed across subtypes (except leptomeningeal)​ Observed across subtypes (except leptomeningeal)​ Chiefly leptomeningeal subtype​ Restricted mutations + observed across subtypes​ Epidemiology​ Most common

29. Slide 29: BTX Cell Therapy and Gene-Editing Pipeline Summary

    BTX Cell Therapy and Gene-Editing Pipeline Summary Indication​ Genetargets​ Delivery​ Discovery​ Preclinical​ IND-enabling​ Clinical​ Comments​ iMSC: iPSC-derived mesenchymal stem cells​ ARDS (all etiologies)​ n/a​ I.V. injection​ ​ ​ ​ ​ NoveCite program​ BMT/HSCT setting​ n/a​ I.V. injection​ ​ ​

30. Slide 30: BTX Will Leverage Best In Class mRNA-based Technologies

    BTX Will Leverage Best In ClassmRNA-based Technologies to Deliver Transformative Regenerative Medicines Exclusive license to foundational mRNA & gene editing IP​Diversified product strategy for multiple clinical applications​Experienced management team with deep expertise in C&GT​Strong partnership

Brooklyn ImmunoTherapeutics — Investor Presentation (November 2021) on 6ix